CORT:NSC-Corcept Therapeutics Incorporated (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 77.64

Change

-0.01 (-0.01)%

Market Cap

USD 1.00B

Volume

1.03M

Analyst Target

USD 15.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 65.38B
ARGX argenx NV ADR

N/A

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.75B
ONC BeiGene, Ltd.

N/A

USD 27.70B
SMMT Summit Therapeutics PLC

N/A

USD 27.07B
RPRX Royalty Pharma Plc

N/A

USD 18.35B
INSM Insmed Inc

N/A

USD 11.84B
INCY Incyte Corporation

N/A

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 11.29B

ETFs Containing CORT

ABLS Abacus FCF Small Cap Lead.. 7.70 % 0.00 %

N/A

N/A
AFSC abrdn Focused U.S. Small .. 6.34 % 0.00 %

N/A

N/A
PSCH Invesco S&P SmallCap Heal.. 5.20 % 0.29 %

N/A

USD 0.15B
FBT:LSE First Trust Global Funds .. 3.50 % 0.00 %

N/A

USD 8.18M
FBTU:LSE First Trust Global Funds .. 3.50 % 0.00 %

N/A

USD 8.18M
VIOG Vanguard S&P Small-Cap 60.. 1.66 % 0.20 %

N/A

USD 0.79B
SEIS SEI Select Small Cap ETF 1.55 % 0.00 %

N/A

USD 0.22B
IDP6:SW iShares S&P SmallCap 600 .. 0.83 % 0.00 %

N/A

USD 2.48B
SMAX iShares Large Cap Max Buf.. 0.57 % 0.00 %

N/A

USD 0.09B
ISP6:LSE iShares III Public Limite.. 0.57 % 0.00 %

N/A

USD 2.48B
ZSML:CA BMO S&P US Small Cap Inde.. 0.55 % 0.00 %

N/A

N/A
SAA ProShares Ultra SmallCap6.. 0.46 % 0.95 %

N/A

USD 0.03B
JPSE JPMorgan Diversified Retu.. 0.42 % 0.29 %

N/A

USD 0.44B
XRS2:SW 0.38 % 0.00 %

N/A

N/A
R2US:SW SPDR® Russell 2000 US Sm.. 0.38 % 0.00 %

N/A

USD 4.18B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

N/A
IJR iShares Core S&P Small-Ca.. 0.00 % 0.07 %

N/A

USD 78.62B
IJT iShares S&P Small-Cap 600.. 0.00 % 0.25 %

N/A

USD 6.00B
SPSM SPDR® Portfolio S&P 600 .. 0.00 % 0.06 %

N/A

USD 11.17B
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

N/A

USD 1.19B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.00 %

N/A

USD 10.02B
GSSC Goldman Sachs ActiveBeta.. 0.00 % 0.20 %

N/A

USD 0.54B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

USD 4.13B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

USD 4.13B
RTWO:LSE L&G Russell 2000 US Small.. 0.00 % 0.00 %

N/A

USD 0.19B
RTWP:LSE Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

USD 0.19B
ETLZ:XETRA L&G Russell 2000 US Small.. 0.00 % 0.00 %

N/A

USD 0.09B
AFSM First Trust Active Factor.. 0.00 % 0.00 %

N/A

USD 0.03B
BKSE BNY Mellon ETF Trust - BN.. 0.00 % 0.00 %

N/A

USD 0.09B
BBSC JPMorgan BetaBuilders U.S.. 0.00 % 0.00 %

N/A

USD 0.54B
FORH Formidable ETF 0.00 % 0.00 %

N/A

USD 0.02B
QVMS Invesco Exchange-Traded F.. 0.00 % 0.00 %

N/A

USD 0.18B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 54.08% 93% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.08% 93% A 94% A
Trailing 12 Months  
Capital Gain 148.77% 96% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 148.77% 96% N/A 96% N/A
Trailing 5 Years  
Capital Gain 412.81% 97% N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 412.81% 97% N/A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 32.45% 74% C 85% B
Dividend Return 32.45% 74% C 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 54.33% 58% F 33% F
Risk Adjusted Return 59.72% 97% N/A 84% B
Market Capitalization 1.00B 97% N/A 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 234.80 15% 17%
Price/Book Ratio 11.13 15% 11%
Price / Cash Flow Ratio 38.20 1% 7%
Price/Free Cash Flow Ratio 51.99 2% 7%
Management Effectiveness  
Return on Equity 23.81% 97% 92%
Return on Invested Capital 19.67% 88% 86%
Return on Assets 11.71% 98% 96%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.